Hematopathology

Hematopathology Indian Medical PG Question 1: Pernicious anemia is associated with which of the following pathologies?

• A. Gastric pathology (Correct Answer)
• B. Renal pathology
• C. Esophageal pathology
• D. Oral pathology

Hematopathology Explanation: **Explanation:** **Pernicious Anemia** is a specific form of megaloblastic anemia caused by an autoimmune destruction of the gastric mucosa [1]. The core pathology is **Autoimmune Metaplastic Atrophic Gastritis (Type A Gastritis)** [3]. 1. **Why Gastric Pathology is Correct:** The disease is characterized by the immune system attacking **gastric parietal cells** (found in the body and fundus of the stomach) and **Intrinsic Factor (IF)** [1], [3]. The loss of parietal cells leads to **achlorhydria** (lack of HCl) and a failure to secrete Intrinsic Factor [1]. Since IF is essential for the absorption of Vitamin B12 in the terminal ileum, its absence leads to Vitamin B12 deficiency, resulting in ineffective erythropoiesis and megaloblastic anemia [1]. 2. **Why Other Options are Incorrect:** * **Renal Pathology:** While B12 is excreted by the kidneys, renal failure does not cause pernicious anemia. * **Esophageal Pathology:** Though patients may have dysphagia (Plummer-Vinson is associated with Iron deficiency, not B12), the primary site of pathology is the stomach. * **Oral Pathology:** Patients often present with **Glossitis** (Beefy red tongue), but this is a *clinical manifestation* of the deficiency, not the underlying *pathological cause* of the disease [4]. **High-Yield Clinical Pearls for NEET-PG:** * **Antibodies:** Anti-parietal cell antibodies (more sensitive) and Anti-intrinsic factor antibodies (more specific) [1], [2]. * **Gastric Morphology:** Characterized by diffuse mucosal atrophy, loss of rugal folds, and **intestinal metaplasia** (replacement of gastric epithelium with goblet cells) [1]. * **Malignancy Risk:** Patients have a 3x increased risk of **Gastric Adenocarcinoma** and Gastric Carcinoid tumors [3]. * **Schilling Test:** Historically used to diagnose B12 malabsorption (now largely replaced by serology). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 592-593. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 655-656. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 771-772. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 772-773.

Hematopathology Indian Medical PG Question 2: A 53-year-old male presents with an enlarged supraclavicular lymph node. Examination reveals enlargement of the Waldeyer ring of oropharyngeal lymphoid tissue. There is no hepatosplenomegaly. Lymph node biopsy reveals replacement by a monomorphous population of large lymphoid cells with enlarged nuclei and prominent nucleoli. The CBC is normal except for mild anemia. Immunohistochemical staining and flow cytometry of the node reveals that most lymphoid cells are CD19+, CD10-, CD3-, CD15-, and TdT negative. What is the most likely diagnosis?

• A. Chronic lymphadenitis
• B. Diffuse large B-cell lymphoma (Correct Answer)
• C. Hodgkin disease
• D. Lymphoblastic lymphoma

Hematopathology Explanation: ### **Explanation** **1. Why Diffuse Large B-cell Lymphoma (DLBCL) is Correct:** The clinical and pathological findings are classic for DLBCL, the most common type of Non-Hodgkin Lymphoma (NHL) [1]. * **Morphology:** The biopsy shows a "monomorphous population of large lymphoid cells" with prominent nucleoli, which is the hallmark of DLBCL [3]. * **Immunophenotype:** The cells are **CD19+** (confirming B-cell lineage) and **TdT negative** (ruling out immature/blastic cells). * **Clinical Presentation:** Involvement of the **Waldeyer ring** and extranodal sites is highly characteristic of DLBCL [3]. It typically presents as a rapidly enlarging symptomatic mass [3]. **2. Why Other Options are Incorrect:** * **Chronic Lymphadenitis:** This would show a pleomorphic (mixed) population of cells (lymphocytes, histiocytes, plasma cells) and preserved lymph node architecture, not a monomorphous large-cell infiltrate. * **Hodgkin Disease:** Characterized by **Reed-Sternberg (RS) cells** in a reactive background [5]. RS cells are typically **CD15+ and CD30+**, but **CD19 negative**. The presentation here lacks the characteristic "bimodal" age distribution or contiguous spread. * **Lymphoblastic Lymphoma:** These are immature cells (precursor T or B cells). They would be **TdT positive** (a marker of immaturity) and typically occur in children or adolescents, often presenting with a mediastinal mass (T-cell type) [4]. **3. NEET-PG High-Yield Pearls:** * **DLBCL** is the most common NHL in adults [2]. * **Waldeyer Ring Involvement:** If mentioned in a lymphoma case, think of DLBCL or Mantle Cell Lymphoma [3]. * **Immunophenotype:** Always check **TdT**. TdT(+) = Lymphoblastic; TdT(-) = Mature Lymphoma [4]. * **BCL-6** is the most common genetic alteration in DLBCL (30% of cases) [2]. * **Treatment:** The standard of care is the **R-CHOP** regimen (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 563-564. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 604. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 604-605. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 606. [5] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 559-560.

Hematopathology Indian Medical PG Question 3: The nucleotide triplet CTC in the sixth position of the beta-globin chain in DNA forms the complementary nucleotide on mRNA that codes for glutamic acid. A point mutation on the beta-globin chain resulting in the nucleotide triplet CAC forms a complementary nucleotide on mRNA that codes for valine. In sickle cell anemia, what is the expected complementary nucleotide triplet on mRNA, read 5' to 3'?

• A. GAG
• B. CTC
• C. GTG
• D. GUG (Correct Answer)

Hematopathology Explanation: The core concept in this question is the molecular pathology of **Sickle Cell Anemia (HbS)** and the process of **transcription**. 1. **Why GUG is correct:** In a normal beta-globin chain, the DNA triplet is **CTC**. During transcription, this acts as a template to form the mRNA codon **GAG**, which codes for **Glutamic acid**. [1] In Sickle Cell Anemia, a point mutation (missense mutation) occurs where Adenine replaces Thymine in the DNA (**CTC → CAC**). When the mutant DNA triplet **CAC** is transcribed into mRNA, the complementary base pairing (C-G, A-U) results in the codon **GUG**. This codon translates to **Valine** at the 6th position of the beta-globin chain. [1], [2] 2. **Analysis of Incorrect Options:** * **A. GAG:** This is the normal mRNA codon for Glutamic acid. Its presence indicates a healthy beta-globin chain. [1] * **B. CTC:** This is the original DNA triplet, not the mRNA codon. mRNA contains Uracil (U) instead of Thymine (T). * **C. GTG:** This represents the DNA sequence of the coding strand (non-template) in the mutation. mRNA cannot contain Thymine (T). **High-Yield Clinical Pearls for NEET-PG:** * **Mutation Type:** Non-conservative missense mutation (Point mutation). [2] * **Substitution:** Glutamic acid (polar/hydrophilic) is replaced by Valine (non-polar/hydrophobic). [1] * **Pathophysiology:** The hydrophobic valine creates a "sticky patch," leading to hemoglobin polymerization under deoxygenated conditions (T-state), causing the characteristic "sickling." [1], [2] * **Electrophoresis:** On alkaline electrophoresis, HbS moves slower than HbA toward the anode because Valine is neutral, whereas Glutamic acid is negatively charged. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 598-599. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 652-654.

Hematopathology Indian Medical PG Question 4: What is the most common type of Non-Hodgkin's Lymphoma (NHL)?

• A. Diffuse large B-cell lymphoma (DLBCL or DLBL) (Correct Answer)
• B. Hairy cell Leukemia
• C. Burkitt's lymphoma
• D. Mantle cell lymphoma

Hematopathology Explanation: **Explanation:** **Diffuse Large B-cell Lymphoma (DLBCL)** is the most common histological subtype of Non-Hodgkin’s Lymphoma (NHL) worldwide, accounting for approximately **30–40%** of all adult cases [1]. It is an aggressive (high-grade) B-cell neoplasm characterized by large, atypical lymphoid cells with prominent nucleoli and a high proliferation index [1]. It can arise *de novo* or as a transformation from a low-grade lymphoma (e.g., Richter’s transformation from CLL/SLL) [1]. **Analysis of Incorrect Options:** * **Hairy Cell Leukemia:** A rare, chronic B-cell lymphoproliferative disorder characterized by "hairy" cytoplasmic projections and TRAP positivity. It is much less common than DLBCL. * **Burkitt’s Lymphoma:** A highly aggressive B-cell lymphoma associated with c-MYC translocation [t(8;14)] [2]. While it is the fastest-growing human tumor, its overall incidence is lower than DLBCL, occurring primarily in children (Endemic form). * **Mantle Cell Lymphoma:** An aggressive B-cell lymphoma associated with t(11;14) and Cyclin D1 overexpression [3]. It accounts for only about 3–10% of NHL cases. **High-Yield Clinical Pearls for NEET-PG:** * **Most common NHL in children:** Lymphoblastic Lymphoma or Burkitt’s Lymphoma (depending on age/region). * **Most common indolent (low-grade) NHL:** Follicular Lymphoma [4]. * **Immunophenotype of DLBCL:** CD19+, CD20+, CD22+, and CD79a+ (Pan B-cell markers). * **Prognostic Index:** The International Prognostic Index (IPI) is used to predict survival in DLBCL patients based on Age, Stage, LDH levels, Performance status, and Extranodal involvement. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 604-605. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 563-564. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 562-563. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 602-604.

Hematopathology Indian Medical PG Question 5: Purpura fulminans is seen in?

• A. Protein C deficiency (Correct Answer)
• B. Protein S deficiency
• C. AT III deficiency
• D. Factor 5 Leiden mutation

Hematopathology Explanation: **Explanation:** **Purpura Fulminans (PF)** is a life-threatening syndrome characterized by sudden, progressive cutaneous hemorrhage and necrosis due to microvascular thrombosis and disseminated intravascular coagulation (DIC). [1] 1. **Why Protein C deficiency is correct:** Protein C is a vitamin K-dependent natural anticoagulant that inactivates Factors Va and VIIIa. In **neonatal homozygous Protein C deficiency**, there is a total absence of this "brake" on the coagulation cascade. This leads to massive, widespread microvascular thrombosis shortly after birth, manifesting as Purpura Fulminans. It can also occur in adults during the initiation of Warfarin therapy (Warfarin-induced skin necrosis) because Protein C has a shorter half-life than other clotting factors, creating a transient hypercoagulable state. 2. **Why the other options are incorrect:** * **Protein S deficiency:** While Protein S is a cofactor for Protein C and its deficiency causes a hypercoagulable state (venous thromboembolism), it is much less commonly associated with the classic presentation of neonatal Purpura Fulminans compared to Protein C. * **Antithrombin III (AT III) deficiency:** This typically presents as heparin resistance and venous thromboembolism (DVT/PE) rather than acute cutaneous necrosis or Purpura Fulminans. * **Factor V Leiden:** This is the most common inherited cause of thrombophilia. It involves a mutation that makes Factor V resistant to inactivation by Protein C. While it increases the risk of DVT, it does not typically cause Purpura Fulminans. **High-Yield Clinical Pearls for NEET-PG:** * **Triad of PF:** Tissue necrosis, DIC, and small vessel thrombosis. [1] * **Warfarin-induced skin necrosis:** Always remember this is due to a transient Protein C deficiency. * **Management:** Acute PF is treated with Protein C concentrate or Fresh Frozen Plasma (FFP). * **Differential:** Purpura Fulminans is also a hallmark of **Meningococcemia** (due to acquired Protein C consumption). [1] **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 672-673.

Hematopathology Indian Medical PG Question 6: What is the cause of alpha thalassemia?

• A. Deletion of alpha genes (Correct Answer)
• B. Deletion of beta genes
• C. Excess of alpha genes
• D. Single amino acid substitution in alpha chain

Hematopathology Explanation: **Explanation:** **1. Why Option A is Correct:** Alpha thalassemia is primarily caused by the **deletion** of one or more of the four alpha-globin genes located on **chromosome 16** [1]. Unlike beta thalassemia, which is usually caused by point mutations, alpha thalassemia results from unequal crossing over during meiosis, leading to the physical loss of gene loci. The severity of the disease depends on the number of genes deleted: * **1 gene deleted:** Silent carrier [1]. * **2 genes deleted:** Alpha-thalassemia trait (mild microcytic anemia) [1]. * **3 genes deleted:** Hemoglobin H (HbH) disease (excess beta chains form tetramers, $\beta_4$) [1], [2]. * **4 genes deleted:** Hydrops Fetalis (Hb Barts, $\gamma_4$; incompatible with life) [1]. **2. Why Other Options are Incorrect:** * **Option B:** Deletion of beta genes is rare; Beta thalassemia is typically caused by **point mutations** in the promoter or splicing sites of the beta-globin gene on chromosome 11 [1]. * **Option C:** Excess alpha genes do not cause thalassemia; however, co-inheritance of extra alpha genes can worsen the clinical severity of beta thalassemia by increasing the globin chain imbalance [3]. * **Option D:** Single amino acid substitutions characterize **Hemoglobinopathies** (e.g., Sickle Cell Anemia, where valine replaces glutamic acid), not the quantitative reduction seen in thalassemia. **3. NEET-PG High-Yield Pearls:** * **Genetics:** Alpha genes are on Chromosome 16; Beta genes are on Chromosome 11. * **Hb Barts:** High affinity for $O_2$, does not deliver it to tissues, leading to intrauterine hypoxia. * **Diagnosis:** Hb electrophoresis is normal in alpha-thal trait; diagnosis often requires genetic testing (PCR) [2]. * **Blood Smear:** Look for "Golf ball cells" (HbH inclusions) when stained with Brilliant Cresyl Blue [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 646-650. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 600-601. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 647-648.

Hematopathology Indian Medical PG Question 7: Which variety of Acute Myeloid Leukemia (AML) is associated with a good prognosis?

• A. M0
• B. M3 (Correct Answer)
• C. M6
• D. M7

Hematopathology Explanation: In Acute Myeloid Leukemia (AML), prognosis is largely determined by the cytogenetic and molecular profile of the blasts. **Why M3 is the correct answer:** AML-M3, also known as **Acute Promyelocytic Leukemia (APL)**, is characterized by the reciprocal translocation **t(15;17)**, which fuses the *PML* and *RARA* genes [1]. While it is a medical emergency due to the high risk of Disseminated Intravascular Coagulation (DIC) [1], it has the **best prognosis** among all AML subtypes. This is because it is highly sensitive to targeted therapy with **All-trans Retinoic Acid (ATRA)** and Arsenic Trioxide, which force the malignant promyelocytes to differentiate into mature neutrophils, leading to high complete remission rates [2]. **Why the other options are incorrect:** * **M0 (Undifferentiated AML):** Associated with a poor prognosis due to the lack of myeloid differentiation and frequent expression of multidrug resistance genes. * **M6 (Erythroleukemia):** Generally carries a poor prognosis and is often associated with complex cytogenetic abnormalities. * **M7 (Megakaryoblastic Leukemia):** Associated with a poor prognosis, especially in adults. (Note: In children with Down Syndrome, M7 has a relatively better outcome, but overall it is considered unfavorable compared to M3). **High-Yield Clinical Pearls for NEET-PG:** * **Morphology:** M3 is characterized by **Auer rods** (often in bundles called **Faggot cells**) [1]. * **DIC:** M3 is the subtype most commonly associated with DIC due to the release of procoagulants from granules [1]. * **Markers:** M3 is typically **HLA-DR negative** and CD34 negative. * **Other Good Prognosis AMLs:** t(8;21) [M2] and inv(16) [M4eo] [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 620-621. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 609-611.

Hematopathology Indian Medical PG Question 8: In thromboasthenia, there is a defect in which of the following processes?

• A. Platelet aggregation (Correct Answer)
• B. Platelet adhesion
• C. Decreased ADP release
• D. Disordered platelet secretion

Hematopathology Explanation: **Explanation:** **Glanzmann Thromboasthenia (GT)** is an autosomal recessive bleeding disorder characterized by a qualitative defect in platelets [1]. 1. **Why Platelet Aggregation is the correct answer:** The underlying defect in GT is a deficiency or dysfunction of the **Glycoprotein IIb/IIIa (GPIIb/IIIa)** complex [1], [2]. This receptor is essential for platelet aggregation because it binds to **fibrinogen**, which acts as a bridge connecting adjacent platelets [2]. Without functional GPIIb/IIIa, platelets cannot aggregate, leading to a prolonged bleeding time despite a normal platelet count [1]. 2. **Why the other options are incorrect:** * **Platelet Adhesion (B):** This is the primary defect in **Bernard-Soulier Syndrome**, where there is a deficiency of **GPIb-IX-V**, the receptor for von Willebrand Factor (vWF) [1]. * **Decreased ADP release / Disordered secretion (C & D):** These refer to **Storage Pool Diseases** (e.g., Gray Platelet Syndrome or Delta-storage pool deficiency), where there is a failure to release granules (Alpha or Dense bodies), rather than a receptor defect for aggregation [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Peripheral Smear:** Platelets appear isolated/individual (no clumping) because they cannot aggregate. * **Platelet Aggregometry:** Characterized by a **failure to respond to all agonists** (ADP, Collagen, Epinephrine, Thrombin) **EXCEPT Ristocetin** [1]. (Note: In Bernard-Soulier, the response to Ristocetin is absent). * **Flow Cytometry:** This is the gold standard for diagnosis, showing decreased expression of CD41 (GPIIb) and CD61 (GPIIIa). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 668-669. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 128.

Hematopathology Indian Medical PG Question 9: What is the rarest variety of multiple myeloma?

• A. IgM
• B. IgD
• C. IgE (Correct Answer)
• D. IgG

Hematopathology Explanation: **Explanation:** Multiple myeloma is a plasma cell neoplasm characterized by the monoclonal proliferation of plasma cells, which typically secrete a specific immunoglobulin (M-protein). The classification of myeloma is based on the type of heavy chain produced [1]. **1. Why IgE is the Correct Answer:** **IgE myeloma** is the rarest form of the disease, accounting for **less than 0.1%** of all multiple myeloma cases. Clinically, it often presents aggressively, frequently manifesting as plasma cell leukemia, and is associated with a poor prognosis. **2. Analysis of Incorrect Options:** * **IgG (Option D):** This is the **most common** variety, accounting for approximately 50–60% of cases [1], [2]. * **IgA:** This is the second most common variety (approx. 20–25%) [1], [2]. * **IgD (Option B):** This is rare (approx. 1–2%) but significantly more common than IgE. It is often associated with Bence-Jones proteinuria and renal failure [1], [2]. * **IgM (Option A):** Extremely rare in classic multiple myeloma [1]. Monoclonal IgM is typically associated with **Waldenström Macroglobulinemia**, not multiple myeloma [2]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Frequency Order:** IgG > IgA > Light chain only (Bence-Jones) > IgD > IgE [1], [2]. * **Non-secretory Myeloma:** Occurs in ~1% of patients where no M-protein is detectable in serum or urine [1]. * **Diagnosis:** Look for the **"CRAB"** features (Calcium elevation, Renal insufficiency, Anemia, Bone lesions). * **Investigation of Choice:** Bone marrow aspiration/biopsy showing >10% clonal plasma cells [3]. * **Serum Protein Electrophoresis (SPEP):** Shows a sharp "M-spike" (usually in the gamma globulin region) [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 608-609. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 616-617. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 617-618.

Hematopathology Indian Medical PG Question 10: BCR ABL gene mutation is seen in which hematologic malignancy?

• A. Chronic Myeloid Leukemia (CML) (Correct Answer)
• B. Acute Myeloid Leukemia (AML)
• C. Chronic Lymphocytic Leukemia (CLL)
• D. Acute Lymphoblastic Leukemia (ALL)

Hematopathology Explanation: The **BCR-ABL1** fusion gene is the hallmark of **Chronic Myeloid Leukemia (CML)** [1]. It results from a reciprocal translocation between chromosomes 9 and 22, known as the **Philadelphia chromosome [t(9;22)(q34;q11)]** [2]. This mutation creates a chimeric protein with constitutive **tyrosine kinase activity**, which drives uncontrolled proliferation of the myeloid lineage [1]. ### Analysis of Options: * **A. Chronic Myeloid Leukemia (CML):** Correct. The Philadelphia chromosome is present in >95% of CML cases [1]. It is essential for diagnosis and serves as the target for Tyrosine Kinase Inhibitors (TKIs) like Imatinib. * **B. Acute Myeloid Leukemia (AML):** While rare cases of AML can be Ph+, it is not a defining feature. Common mutations in AML include *FLT3, NPM1,* and translocations like t(8;21) or t(15;17). * **C. Chronic Lymphocytic Leukemia (CLL):** CLL is characterized by the deletion of 13q, 11q, or trisomy 12. BCR-ABL is not associated with CLL. * **D. Acute Lymphoblastic Leukemia (ALL):** BCR-ABL is seen in approximately 25-30% of adult ALL and 3-5% of pediatric ALL. While present, it is not the *primary* diagnostic association compared to CML, where it is the pathognomonic driver. ### High-Yield Clinical Pearls for NEET-PG: * **The "P"s of CML:** **P**hiladelphia chromosome, **P**roliferation of all myeloid stages, and **P**ositive for BCR-ABL. * **Leukocyte Alkaline Phosphatase (LAP) Score:** Characteristically **decreased** in CML (helps differentiate it from a Leukemoid reaction where LAP is increased). * **Basophilia:** An increase in basophils on a peripheral smear is a strong diagnostic clue for CML. * **Treatment:** Imatinib (Gleevec) is the first-line therapy, acting as a competitive inhibitor of the ATP-binding site on the BCR-ABL enzyme. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 624-625. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 225-226.

Hematopathology Flashcard 1 of 10

Question: Which of the following is a discrete tumor mass arising from lymph nodes? _____

Answer: Lymphoma

Hematopathology Flashcard 2 of 10

Question: What form of non-Hodgkin lymphoma is seen in the image below? _____

Answer: Follicular lymphoma

Hematopathology Flashcard 3 of 10

Question: What type of cell is represented in the image below? _____

Answer: Plasma cell

Hematopathology Flashcard 4 of 10

Question: The given peripheral smear shows abnormal _____ cells with fine hair-like cytoplasmic projections characteristic of hairy cell leukemia.

Answer: B

Hematopathology Flashcard 5 of 10

Question: Tumor cells with multilobulated nuclei (“cloverleaf” or “flower” cells) is characteristic of _____

Answer: Adult T-Cell Leukemia/Lymphoma

Hematopathology Flashcard 6 of 10

Question: Patients with the O blood type cannot receive which blood types? _____

Answer:

Hematopathology Flashcard 7 of 10

Question: What unique antibodies in plasma do patients with the B blood type have? _____

Answer:

Hematopathology Flashcard 8 of 10

Question: Tumor cells with multilobulated nuclei (“cloverleaf” or “flower” cells) which is characteristic of _____ Leukemia/Lymphoma.

Answer: Adult T-Cell

Hematopathology Flashcard 9 of 10

Question: Blood smear of essential _____ shows markedly increased number of platelets, which may be large or abnormally formed

Answer: thrombocythemia

Hematopathology Flashcard 10 of 10

Question: What unique antibodies in plasma do patients with the Rh- blood type have? _____

Answer: